Search Results - "Mayo, Bronwen J."

Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome by Secombe, Kate R., Van Sebille, Ysabella Z. A., Mayo, Bronwen J., Coller, Janet K., Gibson, Rachel J., Bowen, Joanne M.

“…Small molecule receptor tyrosine kinase inhibitors (SM-TKIs) are among a group of targeted cancer therapies, intended to be more specific to cancer cells…”
Get full text

Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea by Bowen, Joanne M., Mayo, Bronwen J., Plews, Erin, Bateman, Emma, Stringer, Andrea M., Boyle, Frances M., Finnie, John W., Keefe, Dorothy M.K.

“…Orally administered small molecule receptor tyrosine kinase inhibitors (RTKIs) are increasingly common treatments for cancer, both alone and in combination…”
Get full text

The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats by Mayo, Bronwen J., Secombe, Kate R., Wignall, Anthony D., Bateman, Emma, Thorpe, Daniel, Pietra, Claudio, Keefe, Dorothy M., Bowen, Joanne M.

“…Purpose Lapatinib is a small molecule tyrosine kinase inhibitor used to treat breast cancer, often in combination with chemotherapy. Diarrhoea commonly occurs…”
Get full text

Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues by Mayo, Bronwen J., Stringer, Andrea M., Bowen, Joanne M., Bateman, Emma H., Keefe, Dorothy M.

“…Purpose A common side effect of irinotecan administration is gastrointestinal mucositis, often manifesting as severe diarrhoea. The damage to the structure and…”
Get full text

Determining the mechanisms of lapatinib-induced diarrhoea using a rat model by Bowen, Joanne M., Mayo, Bronwen J., Plews, Erin, Bateman, Emma, Wignall, Anthony, Stringer, Andrea M., Boyle, Frances M., Keefe, Dorothy M. K.

“…Introduction Diarrhoea caused by treatment with receptor tyrosine kinase inhibitors (TKI) targeting Epidermal Growth Factor Receptors (EGFR) is an important…”
Get full text

Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling by PISHAS, Kathleen I, NEUHAUS, Susan J, MAYO, Bronwen J, HAYCOX, Rebecca C, HO, Kristen, BROWN, Michael P, D'ANDREA, Richard J, EVDOKIOU, Andreas, THOMAS, David M, DESAI, Jayesh, CALLEN, David F, NEILSEN, Paul M, CLAYER, Mark T, SCHREIBER, Andreas W, LAWRENCE, David M, PERUGINI, Michelle, WHITFIELD, Robert J, FARSHID, Gelareh, MANAVIS, Jim, CHRYSSIDIS, Steve

“…Nutlin-3a is a small-molecule antagonist of p53/MDM2 that is being explored as a treatment for sarcoma. In this study, we examined the molecular mechanisms…”
Get full text